Status:
COMPLETED
Isolated Systolic Hypertension in the Elderly and Very Elderly
Lead Sponsor:
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Conditions:
Isolated Systolic Hypertension
Eligibility:
All Genders
65+ years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy of long-term treatment of individually optimized doses of olmesartan medoxomil compared to nitrendipine in elderly and very elderly patients with isolated systolic hypertensio...
Eligibility Criteria
Inclusion
- Age 65 or older
- Mean sitting BP \>160 mmHg and mean sitting dBP\<90 mmHg
Exclusion
- Secondary hypertension
- Malignant hypertension
- Severe Heart Failure (NYHA III-IV)
- Recent history of myocardial infarction
- Hypersensitivity to study medications
- History of drug or alcohol abuse
- History or evidence of renal disease
Key Trial Info
Start Date :
July 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
417 Patients enrolled
Trial Details
Trial ID
NCT00751829
Start Date
July 1 2003
End Date
February 1 2005
Last Update
June 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Munich, Germany